Healthcare-associated meningitis and ventriculitis: diagnosis, treatment and prophylaxis | CMAC

Healthcare-associated meningitis and ventriculitis: diagnosis, treatment and prophylaxis

Clinical microbiology and antimicrobial chemotherapy. 2018; 20(4):260-288

​ Karpov I.A., Shanko Yu.G., Solovey N.V., Zhuravlyov V.A., Gorbich Yu.L., Tanin A.L., Skokova M.V., Reshetnik V.V.
10.36488/cmac.2018.4.260-288
meningitis ventriculitis cerebrospinal fluid shunts cerebrospinal fluid drains central nervous system infections
Section
Guidelines
Type
Journal article
Publication
Clinical microbiology and antimicrobial chemotherapy. 2018; 20(4):260-288

Abstract

Healthcare-associated meningitis and ventriculitis are a common problem of modern public health, which are characterized by diverse etiological spectrum of multidrug resistant microorganisms, presented by difficulties for early diagnosis and adequate treatment, and are often accompanied by a high risk of secondary complications and an unfavorable outcome. This article presents the clinical guidelines of the American Society of Infectious Diseases (IDSA) for the diagnosis and treatment of healthcare-associated meningitis and ventriculitis published in 2017 and may be useful for professionals working with this category of patients.

Igor A. Karpov

Belarusian State Medical University, Minsk, Belarus

Shanko Yu.G.

Republican Scientific Center of Neurology and Neurosurgery, Minsk, Belarus
National Academy of Sciences of Belarus, Minsk, Belarus

Solovey N.V.

Belarusian State Medical University, Minsk, Belarus

Zhuravlyov V.A.

Republican Scientific Center of Neurology and Neurosurgery, Minsk, Belarus
Belarusian State Medical Academy of Postgraduate Education, Minsk, Belarus

Gorbich Yu.L.

Belarusian State Medical University, Minsk, Belarus

Tanin A.L.

Republican Scientific Center of Neurology and Neurosurgery, Minsk, Belarus
Belarusian State Medical Academy of Postgraduate Education, Minsk, Belarus

Skokova M.V.

City Infectious Clinical Hospital, Minsk, Belarus

Reshetnik V.V.

City Infectious Clinical Hospital, Minsk, Belarus

  • 1. Edwards R.J., Drake J.M. Cerebrospinal fluid devices. In: Winn, HR, ed. Youmans & Winn Neurological Surgery. 7th ed. 2017:16381643.
  • 2. Renier D., Lacombe J., Pierre-Kahn A., Sainte-Rose C., Hirsch J.F. Factors causing acute shunt infection. Computer analysis of 1174 operations. J Neurosurg. 1984;61(6):1072-1078.
  • 3. Younger J.J., Simmons J.C., Barrett F.F. Operative related infection rates for ventriculoperitoneal shunt procedures in a children’s hospital. Infect Control. 1987;8(2):67-70.
  • 4. Quigley M.R., Reigel D.H., Kortyna R. Cerebrospinal fluid shunt infections. Report of 41 cases and a critical review of the literature. Pediatr Neurosci. 1989;15(3):111-120.
  • 5. Kontny U., Höfling B., Gutjahr P., et al. CSF shunt infections in children. Infection. 1993;21(2):89-92.
  • 6. Piatt J.H., Carlson C.V. A search for determinants of cerebrospinal fluid shunt survival: retrospective analysis of a 14-year institutional experience. Pediatr Neurosurg. 1993;19(5):233-241; discussion 242.
  • 7. McGirt M.J., Leveque J.-C., Wellons J.C., et al. Cerebrospinal fluid shunt survival and etiology of failures: a seven-year institutional experience. Pediatr Neurosurg. 2002;36(5):248-255.
  • 8. Vinchon M., Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv Syst. 2006;22(7):692697.
  • 9. Conen A., Walti L.N., Merlo A., et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis. 2008;47(1):73-82.
  • 10. Choux M., Genitori L., Lang D., Lena G. Shunt implantation: reducing the incidence of shunt infection. J Neurosurg. 1992;77(6):875-880.
  • 11. Winston K.R. Hair and neurosurgery. Neurosurgery. 1992;31(2):320329.
  • 12. Morissette I., Gourdeau M., Francoeur J. CSF shunt infections: a fifteen-year experience with emphasis on management and outcome. Can J Neurol Sci. 1993;20(2):118-122.
  • 13. van de Beek D., Drake J.M., Tunkel A.R. Nosocomial bacterial meningitis. N Engl J Med. 2010;362(2):146-154.
  • 14. Simon T.D., Butler J., Whitlock K.B., et al. Risk factors for first cerebrospinal fluid shunt infection: findings from a multi-center prospective cohort study. J Pediatr. 2014;164(6):1462-1468.e2.
  • 15. Lozier A.P., Sciacca R.R., Romagnoli M.F., Connolly E.S. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2002;51(1):170-181; discussion 181-182.
  • 16. Ramanan M., Lipman J., Shorr A., Shankar A. A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. BMC Infect Dis. 2015;15:3.
  • 17. Governale L.S., Fein N., Logsdon J., Black P.M. Techniques and complications of external lumbar drainage for normal pressure hydrocephalus. Neurosurgery. 2008;63(4 Suppl 2):379-384; discussion 384.
  • 18. Motta F., Antonello C.E. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014;13(3):301-306.
  • 19. Fjelstad A.-B., Hommelstad J., Sorteberg A. Infections related to intrathecal baclofen therapy in children and adults: frequency and risk factors. J Neurosurg Pediatr. 2009;4(5):487-493.
  • 20. Vender J.R., Hester S., Waller J.L., Rekito A., Lee M.R. Identification and management of intrathecal baclofen pump complications: a comparison of pediatric and adult patients. J Neurosurg. 2006;104(1 Suppl):9-15.
  • 21. Ghosh D., Mainali G., Khera J., Luciano M. Complications of intrathecal baclofen pumps in children: experience from a tertiary care center. Pediatr Neurosurg. 2013;49(3):138-144.
  • 22. Hester S.M., Fisher J.F., Lee M.R., Macomson S., Vender J.R. Evaluation of salvage techniques for infected baclofen pumps in pediatric patients with cerebral palsy. J Neurosurg Pediatr. 2012;10(6):548-554.
  • 23. Wunderlich C.A., Krach L.E. Gram-negative meningitis and infections in individuals treated with intrathecal baclofen for spasticity: a retrospective study. Dev Med Child Neurol. 2006;48(6):450-455.
  • 24. Fily F., Haegelen C., Tattevin P., et al. Deep brain stimulation hardwarerelated infections: a report of 12 cases and review of the literature. Clin Infect Dis. 2011;52(8):1020-1023.
  • 25. Stenehjem E., Armstrong W.S. Central nervous system device infections. Infect Dis Clin North Am. 2012;26(1):89-110.
  • 26. Bergey G.K., Morrell M.J., Mizrahi E.M., et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology. 2015;84(8):810-817.
  • 27. Kourbeti I.S., Vakis A.F., Ziakas P., et al. Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis. J Neurosurg. 2015;122(5):1113-1119.
  • 28. Durand M.L., Calderwood S.B., Weber D.J., et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med. 1993;328(1):21-28.
  • 29. Tsai M.-H., Lu C.-H., Huang C.-R., et al. Bacterial meningitis in young adults in Southern Taiwan: clinical characteristics and therapeutic outcomes. Infection. 2006;34(1):2-8.
  • 30. Castelblanco R.L., Lee M., Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014;14(9):813-819.
  • 31. Guyatt G.H., Oxman A.D., Kunz R., et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049-1051.
  • 32. Guyatt G.H., Oxman A.D., Kunz R., et al. Incorporating considerations of resources use into grading recommendations. BMJ. 2008;336(7654):1170-1173.
  • 33. Guyatt G.H., Oxman A.D., Kunz R., et al. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995-998.
  • 34. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
  • 35. Jaeschke R., Guyatt G.H., Dellinger P., et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
  • 36. George R., Leibrock L., Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg. 1979;51(6):804-811.
  • 37. Schoenbaum S.C., Gardner P., Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis. 1975;131(5):543-552.
  • 38. Walters B.C., Hoffman H.J., Hendrick E.B., Humphreys R.P. Cerebrospinal fluid shunt infection. Influences on initial management and subsequent outcome. J Neurosurg. 1984;60(5):1014-1021.
  • 39. Braxton E.E., Ehrlich G.D., Hall-Stoodley L., et al. Role of biofilms in neurosurgical device-related infections. Neurosurg Rev. 2005;28(4):249-255.
  • 40. Snowden J.N., Beaver M., Smeltzer M.S., Kielian T. Biofilm-infected intracerebroventricular shunts elicit inflammation within the central nervous system. Infect Immun. 2012;80(9):3206-3214.
  • 41. Bryant M.S., Bremer A.M., Tepas J.J., et al. Abdominal complications of ventriculoperitoneal shunts. Case reports and review of the literature. Am Surg. 1988;54(1):50-55.
  • 42. Piatt J.H., Garton H.J.L. Clinical diagnosis of ventriculoperitoneal shunt failure among children with hydrocephalus. Pediatr Emerg Care. 2008;24(4):201-210.
  • 43. Garton H.J., Kestle J.R., Drake J.M. Predicting shunt failure on the basis of clinical symptoms and signs in children. J Neurosurg. 2001;94(2):202-210.
  • 44. Rogers E.A., Kimia A., Madsen J.R., Nigrovic L.E., Neuman M.I. Predictors of ventricular shunt infection among children presenting to a pediatric emergency department. Pediatr Emerg Care. 2012;28(5):405-409.
  • 45. Odio C., McCracken G.H., Nelson J.D. CSF shunt infections in pediatrics. A seven-year experience. Am J Dis Child. 1984;138(12):1103-1108.
  • 46. Mayhall C.G., Archer N.H., Lamb V.A., et al. Ventriculostomyrelated infections. A prospective epidemiologic study. N Engl J Med. 1984;310(9):553-559.
  • 47. Gerner-Smidt P., Stenager E., Kock-Jensen C. Treatment of ventriculostomy-related infections. Acta Neurochir (Wien). 1988;91(1-2):47-49.
  • 48. Walti L.N., Conen A., Coward J., Jost G.F., Trampuz A. Characteristics of infections associated with external ventricular drains of cerebrospinal fluid. J Infect. 2013;66(5):424-431.
  • 49. Chen H.-P., Lai C.-H., Chan Y.-J., et al. Clinical significance of Acinetobacter species isolated from cerebrospinal fluid. Scand J Infect Dis. 2005;37(9):669-675.
  • 50. Hader W.J., Steinbok P. The value of routine cultures of the cerebrospinal fluid in patients with external ventricular drains. Neurosurgery. 2000;46(5):1149-1153; discussion 1153-1155.
  • 51. Wiberg K., Birnbaum A., Gradon J. Causes and presentation of meningitis in a Baltimore community hospital 1997-2006. South Med J. 2008;101(10):1012-1016.
  • 52. Oostenbrink R., Moons K.G., Theunissen C.C., et al. Signs of meningeal irritation at the emergency department: how often bacterial meningitis? Pediatr Emerg Care. 2001;17(3):161-164.
  • 53. Malheiro L., Gomes A., Barbosa P., Santos L., Sarmento A. Infectious Complications of Intrathecal Drug Administration Systems for Spasticity and Chronic Pain: 145 Patients From a Tertiary Care Center. Neuromodulation. 2015;18(5):421-427.
  • 54. Forgacs P., Geyer C.A., Freidberg S.R. Characterization of chemical meningitis after neurological surgery. Clin Infect Dis. 2001;32(2):179185.
  • 55. Schade R.P., Schinkel J., Roelandse F.W., et al. Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. J Neurosurg. 2006;104(1):101-108.
  • 56. Tung H., Raffel C., McComb J.G. Ventricular cerebrospinal fluid eosinophilia in children with ventriculoperitoneal shunts. J Neurosurg. 1991;75(4):541-544.
  • 57. Fulkerson D.H., Boaz J.C. Cerebrospinal fluid eosinophilia in children with ventricular shunts. J Neurosurg Pediatr. 2008;1(4):288-295.
  • 58. Heidemann S.M., Fiore M., Sood S., Ham S. Eosinophil activation in the cerebrospinal fluid of children with shunt obstruction. Pediatr Neurosurg. 2010;46(4):255-258.
  • 59. Pfisterer W., Mühlbauer M., Czech T., Reinprecht A. Early diagnosis of external ventricular drainage infection: results of a prospective study. J Neurol Neurosurg Psychiatry. 2003;74(7):929-932.
  • 60. Pfausler B., Beer R., Engelhardt K., et al. Cell index – a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)related ventriculitis in patients with intraventricular hemorrhage? Acta Neurochir (Wien). 2004;146(5):477-481.
  • 61. Brouwer M.C., Thwaites G.E., Tunkel A.R., van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet. 2012;380(9854):1684-1692.
  • 62. Kim H.-I., Kim S.-W., Park G.-Y., et al. The causes and treatment outcomes of 91 patients with adult nosocomial meningitis. Korean J Intern Med. 2012;27(2):171-179.
  • 63. Nigrovic L.E., Malley R., Macias C.G., et al. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics. 2008;122(4):726-730.
  • 64. Banks J.T., Bharara S., Tubbs R.S., et al. Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections. Neurosurgery. 2005;57(6):1237-1243; discussion 1237-1243.
  • 65. Steinbok P., Cochrane D.D., Kestle J.R. The significance of bacteriologically positive ventriculoperitoneal shunt components in the absence of other signs of shunt infection. J Neurosurg. 1996;84(4):617-623.
  • 66. CDC/NHSN Surveillance Definitions for Specific Types of Infections. January 2015. Available at: www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf. Accessed 11 April 2016.
  • 67. Sundbärg G., Nordström C.H., Söderström S. Complications due to prolonged ventricular fluid pressure recording. Br J Neurosurg. 1988;2(4):485-495.
  • 68. Palabiyikoglu I., Tekeli E., Cokca F., et al. Nosocomial meningitis in a university hospital between 1993 and 2002. J Hosp Infect. 2006;62(1):94-97.
  • 69. Marinovic T., Skrlin J., Vilendecic M., Rotim K., Grahovac G. Multiple Aspergillus brain abscesses in immuno-competent patient with severe cranio-facial trauma. Acta Neurochir (Wien). 2007;149(6):629-632; discussion 632.
  • 70. Mazumder S.A., Cleveland K.O. Cryptococcal meningitis after neurosurgery. Am J Med Sci. 2010;339(6):582-583.
  • 71. Safdieh J.E., Mead P.A., Sepkowitz K.A., Kiehn T.E., Abrey L.E. Bacterial and fungal meningitis in patients with cancer. Neurology. 2008;70(12):943-947.
  • 72. Kainer M.A., Reagan D.R., Nguyen D.B., et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367(23):2194-2203.
  • 73. Smith R.M., Schaefer M.K., Kainer M.A., et al. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med. 2013;369(17):1598-1609.
  • 74. Kauffman C.A., Pappas P.G., Patterson T.F. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med. 2013;368(26):2495-2500.
  • 75. Huy N.T., Thao N.T., Diep D.T., et al. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. Crit Care. 2010;14(6):R240.
  • 76. Sakushima K., Hayashino Y., Kawaguchi T., Jackson J.L., Fukuhara S. Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis. J Infect. 2011;62(4):255-262.
  • 77. Leib S.L., Boscacci R., Gratzl O., Zimmerli W. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Clin Infect Dis. 1999;29(1):69-74.
  • 78. Wong G.K., Poon W.S., Ip M. Use of ventricular cerebrospinal fluid lactate measurement to diagnose cerebrospinal fluid infection in patients with intraventricular haemorrhage. J Clin Neurosci. 2008;15(6):654-655.
  • 79. Maskin L.P., Capparelli F., Mora A., et al. Cerebrospinal fluid lactate in post-neurosurgical bacterial meningitis diagnosis. Clin Neurol Neurosurg. 2013;115(9):1820-1825.
  • 80. Stein M., Schomacher J., Scharbrodt W., Preuss M., Oertel M.F. Cerebrospinal fluid lactate concentration after withdrawal of metabolic suppressive therapy in subarachnoid hemorrhage. Acta Neurochir Suppl. 2012;114:333-337.
  • 81. Schwarz S., Bertram M., Schwab S., Andrassy K., Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med. 2000;28(6):1828-1832.
  • 82. Berger C., Schwarz S., Schaebitz W.R., Aschoff A., Schwab S. Serum procalcitonin in cerebral ventriculitis. Crit Care Med. 2002;30(8):1778-1781.
  • 83. Omar A.S., El Shawarby A., Singh R. Early monitoring of ventriculostomy-related infections with procalcitonin in patients with ventricular drains. J Clin Monit Comput. 2015;29(6):759-765.
  • 84. Li Y., Zhang G., Ma R., et al. The diagnostic value of cerebrospinal fluids procalcitonin and lactate for the differential diagnosis of post-neurosurgical bacterial meningitis and aseptic meningitis. Clin Biochem. 2015;48(1-2):50-54.
  • 85. Deutch S., Dahlberg D., Hedegaard J., et al. Diagnosis of ventricular drainage-related bacterial meningitis by broad-range real-time polymerase chain reaction. Neurosurgery. 2007;61(2):306-311; discussion 311-312.
  • 86. Biesbroek J.M., Verduyn Lunel F.M., Kragt J.J., Amelink G.J., Frijns C.J. Culture-negative Candida meningitis diagnosed by detection of Candida mannan antigen in CSF. Neurology. 2013;81(17):1555-1556.
  • 87. Verweij P.E., Brinkman K., Kremer H.P., Kullberg B.J., Meis J.F. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol. 1999;37(4):11861189.
  • 88. Machetti M., Zotti M., Veroni L., et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis. 2000;2(3):140-144.
  • 89. Malani A.N., Singal B., Wheat L.J., et al. (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal meningitis associated with contaminated methylprednisolone injections. J Clin Microbiol. 2015;53(3):799-803.
  • 90. Lyons J.L., Thakur K.T., Lee R., et al. Utility of measuring (1,3)-β-dglucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection. J Clin Microbiol. 2015;53(1):319-322.
  • 91. Ferreira N.P., Otta G.M., do Amaral L.L., da Rocha A.J. Imaging aspects of pyogenic infections of the central nervous system. Top Magn Reson Imaging. 2005;16(2):145-154.
  • 92. Kline M.W., Kaplan S.L. Computed tomography in bacterial meningitis of childhood. Pediatr Infect Dis J. 1988;7(12):855-887.
  • 93. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284.
  • 94. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82-98.
  • 95. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285-292.
  • 96. Gombert M.E., Landesman S.H., Corrado M.L., et al. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J Neurosurg. 1981;55(4):633636.
  • 97. Nau R., Prange H.W., Menck S., et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother. 1992;29(6):719-724.
  • 98. Dunne W.M., Mason E.O., Kaplan S.L. Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother. 1993;37(12):2522-2526.
  • 99. Gill C.J., Murphy M.A., Hamer D.H. Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J Infect. 2002;45(2):129-132.
  • 100. Milstone A.M., Dick J., Carson B., Siberry G.K. Cerebrospinal fluid penetration and bacteriostatic activity of linezolid against Enterococcus faecalis in a child with a ventriculoperitoneal shunt infection. Pediatr Neurosurg. 2007;43(5):406-409.
  • 101. Yilmaz A., Dalgic N., Müslüman M., et al. Linezolid treatment of shunt-related cerebrospinal fluid infections in children. J Neurosurg Pediatr. 2010;5(5):443-448.
  • 102. Maranich A.M., Rajnik M. Successful treatment of vancomycinresistant enterococcal ventriculitis in a pediatric patient with linezolid. Mil Med. 2008;173(9):927-929.
  • 103. Graham P.L., Ampofo K., Saiman L. Linezolid treatment of vancomycinresistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J. 2002;21(8):798-800.
  • 104. Antony S.J., Hoffman-Roberts H.L., Foote B.S. Use of daptomycin as salvage therapy in the treatment of central nervous system infections including meningitis and shunt infections. Infect Dis Clin Pract 2012;20:161-163.
  • 105. Kullar R., Chin J.N., Edwards D.J., et al. Pharmacokinetics of singledose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother. 2011;55(7):3505-3509.
  • 106. Foster D.R., Rhoney D.H. Enterobacter meningitis: organism susceptibilities, antimicrobial therapy and related outcomes. Surg Neurol. 2005;63(6):533-537; discussion 537.
  • 107. Wolff M.A., Young C.L., Ramphal R. Antibiotic therapy for Enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. Clin Infect Dis. 1993;16(6):772-777.
  • 108. Kim B.-N., Peleg A.Y., Lodise T.P., et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9(4):245-255.
  • 109. Moon C., Kwak Y.G., Kim B.-N., Kim E.S., Lee C.-S. Implications of postneurosurgical meningitis caused by carbapenem-resistant Acinetobacter baumannii. J Infect Chemother. 2013;19(5):916-919.
  • 110. Falagas M.E., Tansarli G.S., Ikawa K., Vardakas K.Z. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272-282.
  • 111. Capitano B., Nicolau D.P., Potoski B.A., et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy. 2004;24(6):803-807.
  • 112. Pappas P.G., Kauffman C.A., Andes D.R., et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e150.
  • 113. Groll A.H., Giri N., Petraitis V., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274-282.
  • 114. Patterson T.F., Thompson G.R., Denning D.W., et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-60.
  • 115. Wen D.Y., Bottini A.G., Hall W.A., Haines S.J. Infections in neurologic surgery. The intraventricular use of antibiotics. Neurosurg Clin N Am. 1992;3(2):343-354.
  • 116. Tamber M.S., Klimo P., Mazzola C.A., Flannery A.M., Pediatric Hydrocephalus Systematic Review and Evidence-Based Guidelines Task Force. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 8: Management of cerebrospinal fluid shunt infection. J Neurosurg Pediatr. 2014;14(Suppl 1):60-71.
  • 117. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Br J Neurosurg 2000;14:7-12.
  • 118. Ziai W.C., Lewin J.J. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol. 2009;22(3):277-282.
  • 119. Pfausler B., Haring H.P., Kampfl A., et al. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin Infect Dis. 1997;25(3):733-735.
  • 120. Pfausler B., Spiss H., Beer R., et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg. 2003;98(5):1040-1044.
  • 121. Wang J.-H., Lin P.-C., Chou C.-H., et al. Intraventricular antimicrobial therapy in postneurosurgical Gram-negative bacillary meningitis or ventriculitis: a hospital-based retrospective study. J Microbiol Immunol Infect. 2014;47(3):204-210.
  • 122. Wilkie M.D., Hanson M.F., Statham P.F., Brennan P.M. Infections of cerebrospinal fluid diversion devices in adults: the role of intraventricular antimicrobial therapy. J Infect. 2013;66(3):239-246.
  • 123. Ng K., Mabasa V.H., Chow I., Ensom M.H. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. Neurocrit Care. 2014;20(1):158-171.
  • 124. Imberti R., Cusato M., Accetta G., et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother. 2012;56(8):44164421.
  • 125. Tängdén T., Enblad P., Ullberg M., Sjölin J. Neurosurgical gramnegative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. Clin Infect Dis. 2011;52(11):1310-1316.
  • 126. Chen K., Wu Y., Wang Q., et al. The methodology and pharmacokinetics study of intraventricular administration of vancomycin in patients with intracranial infections after craniotomy. J Crit Care. 2015;30(1):218. e1-5.
  • 127. Shah S.S., Ohlsson A., Shah V.S. Intraventricular antibiotics for bacterial meningitis in neonates. Cochrane Database Syst Rev. 2012;(7):CD004496.
  • 128. Cook A.M., Mieure K.D., Owen R.D., Pesaturo A.B., Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy. 2009;29(7):832-845.
  • 129. Brown E.M., Edwards R.J., Pople I.K. Conservative management of patients with cerebrospinal fluid shunt infections. Neurosurgery. 2006;58(4):657-665; discussion 657-665.
  • 130. Arnell K., Cesarini K., Lagerqvist-Widh A., Wester T., Sjölin J. Cerebrospinal fluid shunt infections in children over a 13-year period: anaerobic cultures and comparison of clinical signs of infection with Propionibacterium acnes and with other bacteria. J Neurosurg Pediatr. 2008;1(5):366-372.
  • 131. Williamson J.C., Glazier S.S., Peacock J.E. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/ dalfopristin. Clin Neurol Neurosurg. 2002;104(1):54-56.
  • 132. Cruciani M., Navarra A., Di Perri G., et al. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis. 1992;15(2):285-289.
  • 133. Erritouni M., Ktaich N., Rahal J.J., et al. Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. Case Rep Med. 2012;2012:593578.
  • 134. Elvy J., Porter D., Brown E. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother. 2008;61(2):461-462.
  • 135. Jaspan H.B., Brothers A.W., Campbell A.J., et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J. 2010;29(4):379381.
  • 136. Mueller S.W., Kiser T.H., Anderson T.A., Neumann R.T. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium. Ann Pharmacother. 2012;46(12):e35.
  • 137. Katragkou A., Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol. 2005;43(9):4916-4967.
  • 138. Falagas M.E., Bliziotis I.A., Tam V.H. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007;29(1):9-25.
  • 139. Rodríguez Guardado A., Blanco A., Asensi V., et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother. 2008;61(4):908-913.
  • 140. Kestle J.R., Garton H.J., Whitehead W.E., et al. Management of shunt infections: a multicenter pilot study. J Neurosurg. 2006;105(3 Suppl):177-181.
  • 141. Simon T.D., Mayer-Hamblett N., Whitlock K.B., et al. Few Patient, Treatment, and Diagnostic or Microbiological Factors, Except Complications and Intermittent Negative Cerebrospinal Fluid (CSF) Cultures During First CSF Shunt Infection, Are Associated With Reinfection. J Pediatric Infect Dis Soc. 2014;3(1):15-22.
  • 142. Nelson J.D. Cerebrospinal fluid shunt infections. Pediatr Infect Dis. 1984;3(3 Suppl):S30-32.
  • 143. Jones R.F., Stening W.A., Kwok B.C., Sands T.M. Third ventriculostomy for shunt infections in children. Neurosurgery. 1993;32(5):855-859; discussion 860.
  • 144. Shimizu T., Luciano M.G., Fukuhara T. Role of endoscopic third ventriculostomy at infected cerebrospinal fluid shunt removal. J Neurosurg Pediatr. 2012;9(3):320-326.
  • 145. Yogev R. Cerebrospinal fluid shunt infections: a personal view. Pediatr Infect Dis. 1985;4(2):113-118.
  • 146. Schreffler R.T., Schreffler A.J., Wittler R.R. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J. 2002;21(7):632-636.
  • 147. James H.E., Walsh J.W., Wilson H.D., Connor J.D. The management of cerebrospinal fluid shunt infections: a clinical experience. Acta Neurochir (Wien). 1981;59(3-4):157-166.
  • 148. James H.E., Walsh J.W., Wilson H.D., et al. Prospective randomized study of therapy in cerebrospinal fluid shunt infection. Neurosurgery. 1980;7(5):459-463.
  • 149. Whitehead W.E., Kestle J.R. The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons. Pediatr Neurosurg. 2001;35(4):205-210.
  • 150. Turgut M., Alabaz D., Erbey F., et al. Cerebrospinal fluid shunt infections in children. Pediatr Neurosurg. 2005;41(3):131-136.
  • 151. Williams T.A., Leslie G.D., Dobb G.J., Roberts B., van Heerden P.V. Decrease in proven ventriculitis by reducing the frequency of cerebrospinal fluid sampling from extraventricular drains. J Neurosurg. 2011;115(5):1040-1046.
  • 152. Chapman P.H., Borges L.F. Shunt infections: prevention and treatment. Clin Neurosurg. 1985;32:652-664.
  • 153. Stone J., Gruber T.J., Rozzelle C.J. Healthcare savings associated with reduced infection rates using antimicrobial suture wound closure for cerebrospinal fluid shunt procedures. Pediatr Neurosurg. 2010;46(1):19-24.
  • 154. Tulipan N., Cleves M.A. Effect of an intraoperative double-gloving strategy on the incidence of cerebrospinal fluid shunt infection. J Neurosurg. 2006;104(1 Suppl):5-8.
  • 155. Pirotte B.J., Lubansu A., Bruneau M., et al. Sterile surgical technique for shunt placement reduces the shunt infection rate in children: preliminary analysis of a prospective protocol in 115 consecutive procedures. Childs Nerv Syst. 2007;23(11):1251-1261.
  • 156. Haines S.J., Walters B.C. Antibiotic prophylaxis for cerebrospinal fluid shunts: a metanalysis. Neurosurgery. 1994;34(1):87-92.
  • 157. Langley J.M., LeBlanc J.C., Drake J., Milner R. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. Clin Infect Dis. 1993;17(1):98-103.
  • 158. Ratilal B., Costa J., Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. Cochrane Database Syst Rev. 2006;(3):CD005365.
  • 159. Alleyne C.H., Hassan M., Zabramski J.M. The efficacy and cost of prophylactic and perioprocedural antibiotics in patients with external ventricular drains. Neurosurgery. 2000;47(5):1124-1127; discussion 1127-1129.
  • 160. Aucoin P.J., Kotilainen H.R., Gantz N.M., et al. Intracranial pressure monitors. Epidemiologic study of risk factors and infections. Am J Med. 1986;80(3):369-376.
  • 161. Clark W.C., Muhlbauer M.S., Lowrey R., et al. Complications of intracranial pressure monitoring in trauma patients. Neurosurgery. 1989;25(1):20-24.
  • 162. Poon W.S., Ng S., Wai S. CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study. Acta Neurochir Suppl. 1998;71:146-148.
  • 163. Schultz M., Moore K., Foote A.W. Bacterial ventriculitis and duration of ventriculostomy catheter insertion. J Neurosci Nurs. 1993;25(3):158-164.
  • 164. Stenager E., Gerner-Smidt P., Kock-Jensen C. Ventriculostomy-related infections – an epidemiological study. Acta Neurochir (Wien). 1986;83(1-2):20-23.
  • 165. Smith R.W., Alksne J.F. Infections complicating the use of external ventriculostomy. J Neurosurg. 1976;44(5):567-570.
  • 166. Wyler A.R., Kelly W.A. Use of antibiotics with external ventriculostomies. J Neurosurg. 1972;37(2):185-187.
  • 167. Lozier A.P., Sciacca R.R., Romagnoli M.F., Connolly E.S. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2008;62(Suppl 2):688-700.
  • 168. Camacho E.F., Boszczowski I., Basso M., et al. Infection rate and risk factors associated with infections related to external ventricular drain. Infection. 2011;39(1):47-51.
  • 169. Hoefnagel D., Dammers R., Ter Laak-Poort M.P., Avezaat C.J. Risk factors for infections related to external ventricular drainage. Acta Neurochir (Wien). 2008;150(3):209-214; discussion 214.
  • 170. Blomstedt G.C. Results of trimethoprim-sulfamethoxazole prophylaxis in ventriculostomy and shunting procedures. A double-blind randomized trial. J Neurosurg. 1985;62(5):694-697.
  • 171. Sonabend A.M., Korenfeld Y., Crisman C., et al. Prevention of ventriculostomy-related infections with prophylactic antibiotics and antibiotic-coated external ventricular drains: a systematic review. Neurosurgery. 2011;68(4):996-1005.
  • 172. Murphy R.K., Liu B., Srinath A., et al. No additional protection against ventriculitis with prolonged systemic antibiotic prophylaxis for patients treated with antibiotic-coated external ventricular drains. J Neurosurg. 2015;122(5):1120-1126.
  • 173. Govender S.T., Nathoo N., van Dellen J.R. Evaluation of an antibioticimpregnated shunt system for the treatment of hydrocephalus. J Neurosurg. 2003;99(5):831-839.
  • 174. Pattavilakom A., Xenos C., Bradfield O., Danks R.A. Reduction in shunt infection using antibiotic impregnated CSF shunt catheters: an Australian prospective study. J Clin Neurosci. 2007;14(6):526531.
  • 175. Sciubba D.M., Stuart R.M., McGirt M.J., et al. Effect of antibioticimpregnated shunt catheters in decreasing the incidence of shunt infection in the treatment of hydrocephalus. J Neurosurg. 2005;103(2 Suppl):131-136.
  • 176. Kan P., Kestle J. Lack of efficacy of antibiotic-impregnated shunt systems in preventing shunt infections in children. Childs Nerv Syst. 2007;23(7):773-777.
  • 177. Ritz R., Roser F., Morgalla M., et al. Do antibiotic-impregnated shunts in hydrocephalus therapy reduce the risk of infection? An observational study in 258 patients. BMC Infect Dis. 2007;7:38.
  • 178. Thomas R., Lee S., Patole S., Rao S. Antibiotic-impregnated catheters for the prevention of CSF shunt infections: a systematic review and meta-analysis. Br J Neurosurg. 2012;26(2):175-184.
  • 179. Parker S.L., Anderson W.N., Lilienfeld S., Megerian J.T., McGirt M.J. Cerebrospinal shunt infection in patients receiving antibioticimpregnated versus standard shunts. J Neurosurg Pediatr. 2011;8(3):259-265.
  • 180. Attenello F.J., Garces-Ambrossi G.L., Zaidi H.A., Sciubba D.M., Jallo G.I. Hospital costs associated with shunt infections in patients receiving antibiotic-impregnated shunt catheters versus standard shunt catheters. Neurosurgery. 2010;66(2):284-289; discussion 289.
  • 181. Parker S.L., McGirt M.J., Murphy J.A., et al. Comparative effectiveness of antibiotic-impregnated shunt catheters in the treatment of adult and pediatric hydrocephalus: analysis of 12,589 consecutive cases from 287 US hospital systems. J Neurosurg. 2015;122(2):443-448.
  • 182. Zabramski J.M., Whiting D., Darouiche R.O., et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg. 2003;98(4):725-730.
  • 183. Harrop J.S., Sharan A.D., Ratliff J., et al. Impact of a standardized protocol and antibiotic-impregnated catheters on ventriculostomy infection rates in cerebrovascular patients. Neurosurgery. 2010;67(1):187-191; discussion 191.
  • 184. Gutiérrez-González R., Boto G.R., González N., et al. [Effect of antibiotic-impregnated catheters on the incidence of infection after cerebrospinal fluid shunting]. Med Clin (Barc). 2008;131(4):121-124.
  • 185. Tamburrini G., Massimi L., Caldarelli M., Di Rocco C. Antibiotic impregnated external ventricular drainage and third ventriculostomy in the management of hydrocephalus associated with posterior cranial fossa tumours. Acta Neurochir (Wien). 2008;150(10):1049-1055; discussion 1055-1056.
  • 186. Wong G.K., Poon W.S., Ng S.C., Ip M. The impact of ventricular catheter impregnated with antimicrobial agents on infections in patients with ventricular catheter: interim report. Acta Neurochir Suppl. 2008;102:53-55.
  • 187. Sciubba D.M., McGirt M.J., Woodworth G.F., Carson B., Jallo G.I. Prolonged exposure to antibiotic-impregnated shunt catheters does not increase incidence of late shunt infections. Childs Nerv Syst. 2007;23(8):867-871.
  • 188. Park P., Garton H.J., Kocan M.J., Thompson B.G. Risk of infection with prolonged ventricular catheterization. Neurosurgery. 2004;55(3):594-599; discussion 599-601.
  • 189. Holloway K.L., Barnes T., Choi S., et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J Neurosurg. 1996;85(3):419-424.
  • 190. Wong G.K., Poon W.S., Wai S., et al. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2002;73(6):759-761.
  • 191. Kestle J.R., Riva-Cambrin J., Wellons J.C., et al. A standardized protocol to reduce cerebrospinal fluid shunt infection: the Hydrocephalus Clinical Research Network Quality Improvement Initiative. J Neurosurg Pediatr. 2011;8(1):22-29.
  • 192. Hill M., Baker G., Carter D., et al. A multidisciplinary approach to end external ventricular drain infections in the neurocritical care unit. J Neurosci Nurs. 2012;44(4):188-193.
  • 193. Korinek A.-M., Baugnon T., Golmard J.-L., et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery. 2006;59(1):126-133; discussion 126-133.
  • 194. Korinek A.-M., Golmard J.-L., Elcheick A., et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg. 2005;19(2):155-162.
  • 195. Barker F.G. Efficacy of prophylactic antibiotics for craniotomy: a metaanalysis. Neurosurgery. 1994;35(3):484-490; discussion 491-492.
  • 196. Geraghty J., Feely M. Antibiotic prophylaxis in neurosurgery. A randomized controlled trial. J Neurosurg. 1984;60(4):724-726.
  • 197. Schmidt K., Gjerris F., Osgaard O., et al. Antibiotic prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 152 hydrocephalic patients. Neurosurgery. 1985;17(1):1-5.
  • 198. Bratzler D.W., Houck P.M., Surgical Infection Prevention Guidelines Writers Workgroup, American Academy of Orthopaedic Surgeons, American Association of Critical Care Nurses, American Association of Nurse Anesthetists, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38(12):1706-1715.
  • 199. Baltas I., Tsoulfa S., Sakellariou P., et al. Posttraumatic meningitis: bacteriology, hydrocephalus, and outcome. Neurosurgery. 1994;35(3):422-426; discussion 426-427.
  • 200. Heary R.F., Hunt C.D., Krieger A.J., Schulder M., Vaid C. Nonsurgical treatment of compound depressed skull fractures. J Trauma. 1993;35(3):441-447.
  • 201. Bullock M.R., Chesnut R., Ghajar J., et al. Surgical management of depressed cranial fractures. Neurosurgery. 2006;58(3 Suppl):S56-60; discussion Si-iv.
  • 202. Friedman J.A., Ebersold M.J., Quast L.M. Post-traumatic cerebrospinal fluid leakage. World J Surg. 2001;25(8):1062-1066.
  • 203. Eftekhar B., Ghodsi M., Nejat F., Ketabchi E., Esmaeeli B. Prophylactic administration of ceftriaxone for the prevention of meningitis after traumatic pneumocephalus: results of a clinical trial. J Neurosurg. 2004;101(5):757-761.
  • 204. Choi D., Spann R. Traumatic cerebrospinal fluid leakage: risk factors and the use of prophylactic antibiotics. Br J Neurosurg. 1996;10(6):571-575.
  • 205. Levin S., Nelson K.E., Spies H.W., Lepper M.H. Pneumococcal meningitis: the problem of the unseen cerebrospinal fluid leak. Am J Med Sci. 1972;264(4):319-327.
  • 206. Jones S.R., Luby J.P., Sanford J.P. Bacterial meningitis complicating cranial-spinal trauma. J Trauma. 1973;13(10):895-900.
  • 207. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
  • 208. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(25):521-524.
  • 209. Tomczyk S., Bennett N.M., Stoecker C., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822-825.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared